Aptamer Group Ltd, the York-based developer of diagnostic and therapeutic aptamer reagents, is pleased to announce the appointment of Mark Vaux as Chief Operating Officer, with immediate effect.
Mark has held senior and Board level positions in engineering and high technology companies from start-ups to multinational organisations. He joins Aptamer Group from Paraytec Ltd, a scientific instrument company, where he was CEO.
Graduating with a 1st class Double Honours Degree in Engineering and Business Studies, Mark is a Chartered Engineer and Fellow of the Institution of Engineering and Technology.
Mark will oversee Aptamer Group’s operations functions, which employ the latest cutting-edge technologies to deliver aptamer-based solutions to their international customer base for a wide range of research, diagnostic and therapeutic applications.
The company is currently working across a range of important diagnostic and therapeutic targets to support its customers and collaborators. Current collaborations include Valitacell, Cancer Research UK and AstraZeneca.
Mark Vaux said: “I am delighted to join Aptamer Group, which is an innovative and ambitious company leading the way in its field. I have been involved in collaborative projects with the Aptamer team in the past and have always admired their capabilities.
“The scientists here are doing extraordinary work and I hope to bring my experience and skills to the mix to support them in the life-changing projects currently being undertaken by the business.”